Rhythm Pharmaceuticals (RYTM) Reports In-Line Q3 EPS

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.76), in-line with the analyst estimate of ($0.76). Revenue for the quarter came in at $22.5 million versus the consensus estimate of $22.17 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bristow Group to acquire Berry Aviation for $105 million
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)